Skip Navigation

JNCI Journal of the National Cancer Institute 2001 93(24):1886-1888; doi:10.1093/jnci/93.24.1886
© 2001 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Supplementary Table
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Kelley, M. J.
Right arrow Articles by Harpole, D. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kelley, M. J.
Right arrow Articles by Harpole, D. H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 93, No. 24, 1886-1888, December 19, 2001
© 2001 Oxford University Press

BRIEF COMMUNICATION

Genetic Analysis of the {beta}-Tubulin Gene, TUBB, in Non-Small-Cell Lung Cancer

Michael J. Kelley, Sufeng Li, David H. Harpole

Affiliations of authors: M. J. Kelley, S. Li (Department of Medicine), D. H. Harpole (Department of Surgery), Thoracic Oncology Program, Duke University Medical Center, Durham, NC, and Durham Veterans Affairs Hospital.

Correspondence to: Michael J. Kelley, M.D., Hematology/Oncology (111G), Durham Veterans Affairs Hospital, Rm. E3007, 508 Fulton St., Durham, NC 27705 (e-mail: kelleym@duke.edu).

Tubulin, the cellular target for the taxane chemotherapeutic agents, is composed of {alpha}{beta} heterodimers. There are at least six human genes encoding different tubulin {beta} subunits (1). In most epithelial tumor cells, the most highly expressed isoform of {beta}-tubulin is {beta}5, which is encoded by the TUBB gene, also referred to as M40 (2). Chinese hamster ovary cells (3) and an ovarian tumor cell line (4) adapted for growth in vitro in the presence of the taxane paclitaxel have been found to have mutations in TUBB. Monzó et al. (5) reported TUBB mutations in 16 (33%) of 49 tumor samples from previously untreated patients with advanced non-small-cell lung cancer (NSCLC). All of the mutations, except two, were located in exon 4, which encodes more than half of the {beta}-tubulin . . . [Full Text of this Article]

REFERENCES


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
J. J. Lee and S. M. Swain
The Epothilones: Translating from the Laboratory to the Clinic
Clin. Cancer Res., March 15, 2008; 14(6): 1618 - 1624.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. P. Newman, P. A. Foster, C. Stengel, J. M. Day, Y. T. Ho, J.-G. Judde, M. Lassalle, G. Prevost, M. P. Leese, B. V.L. Potter, et al.
STX140 Is Efficacious In vitro and In vivo in Taxane-Resistant Breast Carcinoma Cells
Clin. Cancer Res., January 15, 2008; 14(2): 597 - 606.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Sampath, L. M. Greenberger, C. Beyer, M. Hari, H. Liu, M. Baxter, S. Yang, C. Rios, and C. Discafani
Preclinical Pharmacologic Evaluation of MST-997, an Orally Active Taxane with Superior In vitro and In vivo Efficacy in Paclitaxel- and Docetaxel-Resistant Tumor Models.
Clin. Cancer Res., June 1, 2006; 12(11): 3459 - 3469.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Hari, F. Loganzo, T. Annable, X. Tan, S. Musto, D. B. Morilla, J. H. Nettles, J. P. Snyder, and L. M. Greenberger
Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of {beta}-tubulin (Asp26Glu) and less stable microtubules.
Mol. Cancer Ther., February 1, 2006; 5(2): 270 - 278.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. W.L. Yee, A. Hagey, S. Verstovsek, J. Cortes, G. Garcia-Manero, S. M. O'Brien, S. Faderl, D. Thomas, W. Wierda, S. Kornblau, et al.
Phase 1 Study of ABT-751, a Novel Microtubule Inhibitor, in Patients with Refractory Hematologic Malignancies
Clin. Cancer Res., September 15, 2005; 11(18): 6615 - 6624.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. E. Ferguson, C. Taylor, A. Stanley, E. Butler, A. Joyce, P. Harnden, P. M. Patel, P. J. Selby, and R. E. Banks
Resistance to the Tubulin-Binding Agents in Renal Cell Carcinoma: No Mutations in the Class I {beta}-Tubulin Gene but Changes in Tubulin Isotype Protein Expression
Clin. Cancer Res., May 1, 2005; 11(9): 3439 - 3445.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Goodin, M. P. Kane, and E. H. Rubin
Epothilones: Mechanism of Action and Biologic Activity
J. Clin. Oncol., May 15, 2004; 22(10): 2015 - 2025.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. L. McLeod
Genetic Strategies to Individualize Supportive Care
J. Clin. Oncol., June 15, 2002; 20(12): 2765 - 2767.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
M. Monzo, M. Taron, and R. Rosell
Re: Genetic Analysis of the {beta}-Tubulin Gene, TUBB, in Non-Small-Cell Lung Cancer
J Natl Cancer Inst, May 15, 2002; 94(10): 774 - 776.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
S. Sale, P. J. Oefner, and B. I. Sikic
Re: Genetic Analysis of the {beta}-Tubulin Gene, TUBB, in Non-Small-Cell Lung Cancer
J Natl Cancer Inst, May 15, 2002; 94(10): 776 - 777.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
M. J. Kelley
RESPONSE: Re: Genetic Analysis of the {beta}-Tubulin Gene, TUBB, in Non-Small-Cell Lung Cancer
J Natl Cancer Inst, May 15, 2002; 94(10): 777 - 777.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
F. J. Kaye
Publishing Negative Data: {beta}-Tubulin Mutations in Lung Cancer
J Natl Cancer Inst, December 19, 2001; 93(24): 1832 - 1833.
[Full Text] [PDF]